Evidence of effectiveness of herbal medicinal products in the treatment of arthritis part 2: Rheumatoid arthritis

Phytotherapy Research

Volumn 23, Issue 12, 2009, Pages 1647-1662

  Cameron, Melainie ^a,b   Gagnier, Joel J ^c   Little, Christine V ^d   Parsons, Tessa J ^e   Blümle, Anette ^f   Chrubasik, Sigrun ^g  

^a VICTORIA UNIVERSITY   (Australia)

^b AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^c UNIVERSITY OF MICHIGAN   (United States)

^d BOURNEMOUTH UNIVERSITY   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Clinical trials; Cochrane review; Effectiveness; Herbal therapy; Osteoarthritis

Indexed keywords

ARLACEL 165; BLACK CURRANT EXTRACT; BORAGE OIL; BOSWELLIA SERRATA EXTRACT; CAPSAICIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA LINOLENIC ACID; HERBACEOUS AGENT; KRALLENDORN; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTODOLOR; PHYTODOLOR N; PLACEBO; PRIMROSE OIL; PRUNELLA VULGARIS EXTRACT; RA 1; SALIX EXTRACT; SKI 306X; TANACETUM PARTHENIUM EXTRACT; THUNDER GOD VINE; TRICHOSANTHES EXTRACT; TRIPTERYGIUM WILFORDII EXTRACT; UNCARIA TOMENTOSA EXTRACT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CLEMATIS MANDSHURICA; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; GASTROINTESTINAL SYMPTOM; HEADACHE; HERBAL MEDICINE; HUMAN; LOOSE FECES; META ANALYSIS; NAUSEA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SKIN ALLERGY; SYSTEMATIC REVIEW; UNCARIA;

ARTHRITIS, RHEUMATOID; GAMMA-LINOLENIC ACID; HERBAL MEDICINE; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIPTERYGIUM;

BORAGINACEAE; OENOTHERA; TRIPTERYGIUM WILFORDII;

EID: 73449132248     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3006     Document Type: Review

References (152)

1. ACR - American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. 2002. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46: 328-346.
2. Aguilar JL, Rojas P, Marcelo A, Plaza A, Bauer R, Reininger E, Klaas CA, Merfort I. 2002. Anti-infl ammatory activity of two different extracts of Uncaria tormentosa (Rubiaceae). J Ethnopharm 81: 271-276.
3. Allen-Hall L, Cano P, Arnason JT, Rojas R, Lock O, Lafrenie RM. 2007. Treatment of THP-1 cells with Uncaria tomentosa extracts differentially regulates the expression if IL-1beta and TNF-alpha. J Ethnopharm 109: 312-317.
4. Altmann A, Poeckel D, Fischer L, Schubert-Zsilavecz M, Steinhilber D, Werz, O. 2004. Coupling of boswellic acid-induced Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes. B. J Pharmacol 141: 223-232.
5. Ammon HP, Mack T, Singh GB, Safayhi H. 1991. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia errata. Planta Med 57: 203-207.
6. Ammon HP, Safayhi H, Mack T, Sabieraj J. 1993. Mechanism of anti-infl ammatory actions of curcumine and boswellic acids. J Ethnopharmacol 38: 113-119.
7. Andersen MB, Stoové MA. 1998. The sanctity of p > .05 obfuscates good stuff: A comment on Kerr and Goss. J Appl Sport Psychol 10: 168-173.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang HH, Luthra HS, Medsger Jr TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. 1988. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
9. Astin JA. 1998. Why patients use alternative medicine: Results of a national study. JAMA 279: 1548-1553.
10. Atherton DJ. 1994. Towards the safer use of traditional remedies. BMJ 308: 673-674.
11. Begg C, Cho M, Eastwood S, Horeton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. 1996. Improving the Quality of Reporting of Randomized Controlled Trials. The CONSORT Statement. JAMA 276: 637-639.
12. Belch JJF, Ansell D, Madhok R, O'Dowd A, Sturrock D. 1988. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-infl ammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. Ann Rheum Dis 47: 96-104.
13. Biegert C, Wagner I, Ludtke R, Kotter I, Lohmuller C, Gunaydin I, Taxis K, Heide L. Effi cacy and safety of willow bark extract in the treatment of osteoarthritis and rheumtoid arthritis: Results of 2 randomized double-blind controlled trials. 2004. J Rheumatol 31: 2121-2130.
14. Boisset M, Fitzcharles M. 1994. Alternative medicine use by rheumatology patients in a universal health care setting. J Rheumatol 21: 148-152.
15. Brzeski M, Madhol R, Capell HA. 1991. Evening primrose oil in patients with rheumatoid arthritis and side-effects of nonsteroidal anti-infl ammatory drugs. Br J Rheumatol 30: 370-372.
16. Buchbinder R, Gingold M, Hall S, Cohen M. 2002. Nonprescription complementary treatments used by rheumatoid arthritis patients attending a community-based rheumatology practice. Int Med J 23: 208-214.
17. Buck SH, Burks TF. 1986. THe neuropharmacology of capsaicin: Review of some recent observations. Pharm Rev 38: 179-226.
18. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. 2000. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7: 273-282.
19. Canter PH, Lee HS, Ernst E. 2006. A systematic review of randomised clinical trials of Tripterygium wilfordii for rheumatoid arthritis. Phytomedicine 13: 371-377.
20. Capasso F. 1986. The effect of an aqueous extract of Tanacetum parthenium L. on arachidonic acid metabolism by rat peritoneal leucocytes. J Pharm Pharmacol 38: 71-72.
21. Chang DM, Chang WY, Kuo SY, Chang ML. 1997. The effects of traditional antirheumatic herbal medicines on immune response cells. J Rheumatol 24: 436-441.
22. Chevrier MR, Ryan AE, Lee DY, Zhongze M, Wu-Yan Z, Via CS. 2005. Boswellia carterii extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro. Clin Diagn Lab Immunol 12: 75-80.
23. Chilton-Lopez, Surette ME, Swan DD, Fonteh AN, Johnson MM, Chilton FH. 1996. Metabolism of gammalinolenic acid in human neutrophils. J Immunol 156: 2941-2947.
24. Choi JH, Choi JH, Kim DY, Yoon JH, Youn HY, Yi JB, Rhee HI, Ryu KH, Jung K, Han CK, Kwak WJ, Cho YB. 2002. Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model. Osteoarthritis Cartilage 10: 471-478.
25. Chopra A, Lavin P, Patwardhan B, Chitre D. 2000. Randomized double-blind trial of an Ayurvedic plant derived formulation for treatment of rheumatoid arthritis. J Rheumatol 27: 1365-1372.
26. Chou CT, Chang SC. 1998. The inhibitory effect of common traditional anti-rheumatic herb formulas on prostaglandin E and interleukin 2 in vitro: a comparative study with Tripterygium wilfordii. J Ethnopharmacol 62: 167-171.
27. Chrubasik S, Eisenberg E. 1998. Treatment of rheumatic pain with herbal medicine in Europe. Pain Digest 8: 231-236.
28. Chrubasik S, Wink M. 1998. Traditional herbal therapy for the treatment of rheumatic pain: Preparations from Devil's Claw and Stinging Nettle. Pain Digest 8: 94-101.
29. Chrubasik JE, Roufogalis BD, Chrubasik S. 2007. Evidence of effectiveness of herbal anti-infl ammatory drugs in the treatment of painful osteoarthritis including chronic low back pain. Phytother Res 21: 675-683.
30. Cibere J, Deng Z, Lin Y, He Y, Wang Z, Thorne A, Lehman AJ, Tsang IK, Esdale JM. 2003. A randomized double blind placebo controlled trial of topical Tripterygium wilfordii in rheumatoid arthritis: Reanalyais using logistic regression. J Rheumatol 30: 465-467.
31. Collier HO, Butt NM, McDonald-Gibson WJ, Saeed SA. 1980. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet 2: 922-923.
32. Cronan TA, Kaplan RM, Posner L, Blumberg E, Franklin K. 1989. Prevalence of the use of unconventional remedies for arthritis in a metropolitan community. Arthritis Rheum 32: 1604-1607.
33. Deal CL, Schnitzer TJ, Lipstein E, Seibold JR, Stevens RM, Levy MD, Albert D, Renold F. 1991. Treatment of arthritis with topical capsaicin: A double-blind trial. Clin Ther 13: 383-395.
34. Dedov VN, Roufogalis BD. 2000. Mitochondrial calcium accumulation following activation of vanilloid (VR1) receptors by capsaicin in dorsal root ganglion neurons. Neurosci 95: 183-188.
35. DeLuca P, Rossetti RG, Alavian C, Karim P, Zurier RB. 1999. Effects of gammalinolenic acid on interleukin-1 beta and tumor necrosis factor-alpha secretion by stimulated human peripheral blood monocytes: studies in vitro and in vivo. J Invest Med 47: 246-250.
36. Dooper MM, van Riel B, Graus YM, M'Rabet L. 2003. Dihomogamma-linolenic acid inhibits tumour necrosis factor-alpha production by human leucocytes independently of cyclooxygenase activity. Immunology 110: 348-357.
37. Eberl R, Dunky A, Leeb B, Wohanka A. 1988. Savings of nonsteroidal antirheumatics by Phytodolor: Placebo-controlled, double blind study over a period of one year per patient. Unpublished report for steigerwald pharmaceuticals. Author: Darmstadt, Germany.
38. EFPIA - European Federation of Pharmaceutical Industries and Associations. Available at www.gmp-compliance.org/eca-guidelinelist-part3.html. Accessed: 10 June 2008.
39. Ernst E, Willoughby M, Weihmayr TH. 1995. Nine possible reasons for choosing complemetary medicine. Perfusion 8: 356-358.
40. Ernst E. 1995. Bitter pills of nature: Safety issues in complementary medicine. Pain 60: 237-238.
41. Ernst E. 1996. Plants as medicine: possible benefi ts and potential risks. Br J Ther Rehab 3: 82, 99-100.
42. Ernst E. 1998. Over-the-counter complementary remedies used for arthritis. Pharmaceut J 260: 830-831.
43. ESCOP - European Scientifi c Cooperative on Phytotherapy. 2003. ESCOP Monographs. Thieme-Verlag Stuttgart: New York.
44. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus M, Tugwell P, Weinblatt M, Widmark R, Williams MJ, Wolfe F. 1993. The American College of Rheumatology preliminary core set of disease activity measures for rhematoid arthritis clinical trials. Arthritis Rheum 36: 729-740.
45. Felson DT, Andersen JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot Jr R, Paulus M, Strand V, Tugwell P, Weinblatt M, Williams MJ, Wolfe F, Kieszak, S. 1995. American College of Rheumatology preliminary defi - nition of improvement in rheumatoid arthritis. Arthritis Rheum 38: 727-735.
46. Felts W, Yelin E. 1989. The economic impact of the rheumatic diseases in the United States. J Rheumatol 16: 867-884.
47. Fiebich BL, Chrubasik S. 2004. Effects of an ethanolic salix extract on the release of selected infl ammatory mediators in vitro. Phytomedicine 11: 135-138.
48. Fitzgerald M. 1983. Capsaicin and sensory neuron. A review. Pain 15: 109-130.
49. Flynn DL, Rafferty MF, Boctor AM. 1986. Inhibition of human neutrophil 5-lipoxygenase activity by gingerdione, shogaol, capsaicin and related pungent compounds. Prostoglandins Leukot Med 24: 195-198.
50. Fukuda K, Hibiya Y, Mutoh M, Ohno Y, Yamashita K, Akao S, Fujiwara H. 2000. Inhibition by parthenolide of phorbol ester-induced transcriptional activation of inducible nitric oxide synthase gene in a human monocyte cell line THP-1. Biochem Pharmacol 60: 595-600.
51. Furse RK, Rossetti RG, Zurier RB. 2001. Gammalinolenic acid, an unsaturated fatty acid with anti-infl ammatory properties, blocks amplifi cation of IL-1 beta production by human monocytes. J Immunol 67: 490-496.
52. Furse RK, Rossetti RG, Seiler CM, Zurier RB. 2002. Oral administration of gammalinolenic acid, an unsaturated fatty acid with anti-infl ammatory properties, modulates interleukin-1beta production by human monocytes. J Clin Immunol 22: 83-91.
53. Gayathri B, Manjula N, Vinaykumar KS, Lakshmi BS, Balakrishnan A. 2007. Pure compound from Boswellia serrata extract exhibits anti-infl ammatory property in human PBMCs and mouse macrophages through inhibition of TNFá, IL-1â, NO and MAP kinases. Int Immunopharmacol 7: 473-482.
54. Glaser T, Winter S, Groscurth P, Safayhi H, Sailer ER, Ammon HP, Schabet M, Weller M. 1999. Boswellic acids and malignant glioma: Induction of apoptosis but no modulation of drug sensitivity. Br J Cancer 80: 756-765.
55. Glinko A. 1998. Pharmacological properties of a standardized extract from Willow bark (Cortex salicis). Thesis: Pomeranian Academy of Medicine, Poland.
56. Goncalves C, Dinis T, Batista MT. 2005. Antioxidant properties of pro-anthocyanidins of Uncaria tomentosa bark decoction: A mechanism for anti-infl ammatory activity. Phytochemistry 66: 89-98.
57. Gürbüz I, Ustün O, Yesilada E, Sezik E, Kutsal O. 2003. Antiulcerogenic activity of some plants used as folk remedy in Turkey. J Ethnopharmacol 88: 93-97.
58. Gundermann KJ. 2001. Clinical expert report. Steigerwald: Darmstadt, Germany.
59. Guo W, Ma L, Tao X. 2001. [In vitro inhibitive effects of Tripterygium wilforii on NO production, iNOS activity, and iNOSmRNA expression in chondrocyrtes of patients with rheumatoid arthritis] [Article in Chinese]. Zhonghua Yi Xue Za Zhi 81: 1035-1037.
60. Hartwich A, Germann I, Kelber O, Muller J, Weiser D, Heinle H. 2006. Das pfl anzliche Rheumapräparat STW 1 hat antioxidative Effekte. Zschr Rheumatol 65(Supp 1): 528.
61. Higgins JPT, Green S. 2008. The Cochrane Handbook for Systematic Review of Interventions. Wiley-Blackwell: Chichester, UK.
62. Ho LJ, Chang DM, Chang ML, Kuo SY, Lai JH. 1999. Mechanism of immunosuppression of the antirheumatic herb TWHf in human T cells. J Rheumatol 26: 14-24.
63. Hwang D, Fischer NH, Jang BC, Tak H, Kim JK, Lee W. 1996. Inhibition of the expression of inducible cyclooxygenase and proinfl ammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 226: 810-818.
64. ICH 2004. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: Synopsis of ICH guidelines and topics. Author: Geneva, Switzerland.
65. Iverson L, Fogh K, Kragbelle K. 1992. Effect of dihomogammalinolenic acid and its 15-lipoxygenase metabolite on eicosanoid metabolism by human mononuclear leukocytes in vitro: Selective inhibition of the 5-lipoxygenase pathway. Arch Dermatol Res 284: 222-226.
66. Jäntti J, Seppala E, Vapaatalo H, Isomaki H. 1989a. Evening primrose oil and olive oil in treatment of rheumatoid arthritis. Clin Rheumatol 8: 238-234.
67. Jäntti J, Nikkari T, Solakivi T, Vapaatalo H, Isomake H. 1989b. Evening primrose oil in rheumatoid arthritis: changes in serum lipids and fatty acids. Ann Rheum Dis 48: 124-127.
68. Jancso G, Kiraly E. 1981. Capsaicin-induced degeneration of neuron in brain. Brain Res 210: 83-89.
69. Jiang WG, Puntis MC, Horrobin DF, Scott C, Hallett MB. 1996. Inhibition of neutrophil respiratory burst and cytokine priming by gamma-linolenic acid. Br J Surg 83: 659-664.
70. Jürgensen S, Dalbo S, Angers P, Santos AR, Ribeiro-do-Valle RM. 2005. Involvement of 5-HT2 receptors in the antinociceptive effect of Uncaria tomentosa. Pharmacol Biochem Behav 81: 466-477.
71. Kahkonen MP, Hopia AI, Vuorela HJ, Rauha JP, Pihlaja K, Kujala TS, Heinonen M. 1999. Antioxidant activity of plant extracts containing phenolic compounds. J Agric Food Chem 47: 3954-3962.
72. Kang BY, Chung SW, Kim TS. 2001. Inhibition of interleukin-12 production in lipopolysaccharide-activated mouse macrophages by parthenolide, a predominant sesquiterpene lactone in Tanacetum parthenium: involvement of nuclear factor-kappaB. Immunol Lett 77: 159-163.
73. Khajuria A, Gupta A, Suden P, Singh S, Malik F, Singh J, Gupta BD, Suri KA, Srinivas VK, Ella K, Qazi GN. 2008. Immunomodulatory activity of biopolymeric fraction BOS 2000 from Boswellia serrata. Phytother Res 22: 340-348.
74. Khayyal MT, El-Ghazaly MA, Abdallah DM, Okpanyi SN, Kelber O, Weiser D. 2005. Mechanisms involved in the antiinfl ammatory effect of a standardized willow bark extract. Arzneimittel-Forschung/Drug Res 55: 677-687.
75. Kim YH, Lee SH, Lee JY, Choi SW, Park JW, Kwon TK. 2004. Triptolide inhibits murine-inducible nitric oxide synthase expression by down-regulating lipopolysaccharide-induced activity of nuclear factor-kappa B and c-Jun NH2-terminal kinase. Eur J Pharmacol 494: 1-9.
76. Kim JH, Ryu KH, Jung KW, Han CK, Kwak WJ, Cho YB. 2005a. Effects of SKI306X on arachidonate metabolism and other infl ammatory mediators. Bio Pharm Bulletin 28: 1615-1620.
77. Kim JH, Ryu KH, Jung KW, Han CK, Kwak WJ, Cho YB. 2005b. SKI306X suppresses cartilage destruction and inhibits the production of matrix metalloproteinase in rabbit joint cartilage explant culture. J Pharmacol Sci 98: 298-306.
78. Krivoy N, Pavlotzky E, Chrubasik S, Eisenberg E, Brooks G. 2001. Effect of Salicis Cortex extract on human platelet aggregation. Planta Med 67: 209-213.
79. Kuppsamy UR, Khoo HE, Das NP. 1990. Structure-activity studies of fl avonoids as inhibitors of hyaluronidase. Biochem Pharmacol 140: 397-401.
80. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. 2001. The anti-infl ammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 8: 759-766.
81. Lawson SN, Nickels SM. 1980. The use of morphometric techniques to analyze the effect of neonatal capsaicin treatment on rat dorsal root ganglia and dorsal root. J Physiol 302: 12.
82. Lee DM, Weinblatt ME. 2001. Rheumatoid arthritis. Lancet 358: 903-911.
83. Lemaire I, Assinewe V, Cano P, Awang DV, Arnason JT. 1999. Stimulation of interleukin-1 and 6 production in alveolar macrophages by the neotropical liana, Uncaria tomentosa (una de gato). J Ethnopharmacol 64: 109-115.
84. Leventhal LJ, Boyce EG, Zurier RB. 1993. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Int Med 119: 867-873.
85. Leventhal LJ, Boyce EG, Zurier RB. 1994. Treatment of rheumatoid arthritis with blackcurrant seed oil. Br J Rheumatol 33: 847-852.
86. Li RW, David Lin G, Myers SP, Leach DN. 2003. Antiinfl ammatory activity of Chinese medicinal vine plants. J Ethnopharmacol 85: 61-67.
87. Lin N, Liu C, Xiao C, Jia H, Imada K, Wu H, Ito A. 2007. Triptolide, a diterpenoid triepoxide, suppresses infl ammation and cartilage destruction in collagen-induced arthritis mice. Biochem Pharmacol 73: 136-146.
88. Li-Weber M, Giaisi M, Treiber MK, Krammer PH. 2002. The anti-infl ammatory sesquiterpene lactone parthenolide suppresses IL-4 gene expression in peripheral blood T. Eur J Immunol 32: 3587-3597.
89. Lin N, Sato T, Ito A. 2001. Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production 2001. and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fi broblasts. Arthritis Rheum 44: 2193-2200.
90. Little CV, Parsons T. 2001. Herbal therapy for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No: CD002948. DOI.10.1002/14651858. CD002948.
91. Liu Q, Chen T, Chen G, Shu X, Sun A, Ma P, Lu L, Cao X. 2007. Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NFkappaB pathways. Molec Immunol 44: 2686-2696.
92. Lorig K, Holman H. 1989. Long-term outcomes of an arthritis self-management study: Effects of reinforcement efforts. Soc Sci Med 29: 221-224.
93. MacPherson H, Blackwell R. 1994. Rheumatoid arthritis and Chinese medicine. Eur J Oriental Med 1: 17-29.
94. Maekawa K, Yoshikawa N, Du J, Nishida S, Kitasato H, Okamoto K, Tanaka H, Mizushima Y, Kawai S. 1999. The molecular mechanism of inhibition of interleukin-1beta-induced cyclooxygenase-2 expression in human synovial cells by Tripterygium wilfordii Hook F extract. Infl amm Res 48: 575-581.
95. McCarthy GM, McCarthy DJ. 1992. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol 19: 604-607.
96. Meier G. 1987. Phytodolor N versus placebo in rheumatoid arthritis: Pilot study of the rheumatism clinic. Unpublished report for steigerwald pharmaceuticals. Darmstadt, Germany.
97. Meyer B, Schneider W, Elstner EF. 1995. Antioxidative properties of alcoholic extracts from Fraxinus excelsior, Populus tremula and Solidago virgaurea. Arzneimittel-Forschung/ Drug Res 45: 174-176.
98. Miller MJ, Ahmed S, Bobrowski P, Haqqi TM. 2006. The chrondoprotective actions of a natural product are associated with the activation of IGF-1 production by human chondrocytes despite the presence of IL-1beta. BMC Compl Alternat Med 7: 6-13.
99. Mills SY, Jacoby RK, Chacksfi eld M, Willoughby M. 1996. Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: A double-blind study. Br J Rheumatol 35: 874-878.
100. Mittra S, Datta A, Singh SK, Singh A. 2000. 5-Hydroxytryptamineinhibiting property of feverfew: Role of parthenolide content. Acta Pharmacol Sin 21: 1106-1114.
101. Moher D, Schulz KF, Altman DG. 2001. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Int Med 134: 657-662.
102. Mur E, Hartig F, Eibl G, Schirmer M. 2002. Randomised double blind trial of an extract from the pentacyclid alkaloid-chemotype of Uncaria tomentosa for the treatment of rheumatoid arthritis. J Rheumatol 29: 678-681.
103. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. 1999. Topical capsaicin in humans: Parallel loss of epidermal nerve fi bers and pain sensation. Pain 81: 135-145.
104. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, Shekelle P. 2002. A meta-analysis of severe upper gastrointestinal complications of nonsteroidal antiinfl ammatory drugs. J Rheumatol 29: 804-812.
105. O'Gradaigh D, Ireland D, Bord S, Compston JE. 2004. Joint erosion in rheumatoid arthritis: Interactions between tumor necrosis factor alpha, interleukin 1, and receptor activator of nulcear factor kappaB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 63: 354-359.
106. Pattrick M, Heptinstall S, Doherty M. 1989. Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Ann Rheum Dis 48: 547-549.
107. Piela-Smith TH, Liu X. 2001. Feverfew extracts and the sesquiterpene lactone parthenolide inhibit intercellular adhesion molecule-1 expression in human synovial fi broblasts. Cell Immunol 209: 89-96.
108. Pilarski R, Zielinski H, Ciesiolka D, Gulewicz K. 2006. Antioxidant activity of ethanolic and aqueous extracts of Uncaria tomentosa (Willd.) DC. J Ethnopharmacol 104: 18-23.
109. Pittler MH, Ernst E. 2004. Feverfew for preventing migraine. Cochrane Dataase of Systematic Reviews 1: CD002286.
110. Poeckel D, Tausch L, Kather N, Jauch J, Werz O. 2006. Boswellic acids stimulate arachidonic acid release and 12-lipoxygenase activity in human platelets independent of Ca2+ and differentially interact with platelet-type 12-lipoxygenase. Mol Pharmacology 70: 1071-1078.
111. Pugh WJ, Sambo K. 1988. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol 40: 743-745.
112. Purasiri P, Mckechnie A, Heys SD, Eremin O. 1997. Modulation in vitro of human natural cytotoxicity, lymphocyte proliferative response to mitogens and cytokine production by essential fatty acids. Immunology 92: 166-172.
113. Rizzi R, Re F, Bianchi A, De Feo V, de Simone F, Bianchi L, Stivala LA. 1993. Mutagenic and antimutagenic activities of Uncaria tormentasa and its extracts. J Ethnopharmacol 38: 63-77.
114. Rohnert U, Schneider W, Elster EF. 1998a. Superoxid-dependent and -independent nitrite formation from hydroxylamine: Inhibition by plant extracts. Zeitschr Naturforsch 53: 241-249.
115. Rohnert U, Koske D, Schneider W, Elstner E. 1998b. Inhibition by Salix extracts and Phytodolor of copper-catalyzed oxidative destructions. Zeitschr Naturforsch 53: 233-240.
116. Roy S, Khanna S, Shah H, Rink C, Phillips C, Preuss H, Subbaraju GV, Trimurtulu G, Krishnaraju AV, Bagchi M, Bagchi D, Sen CK. 2005. Human genome screen to identify the genetic basis of the anti-infl ammatory effects of Boswellia in microvascular endothelial cells. DNA Cell Biol 24: 244-255.
117. Roy S, Khanna S, Krishnaraju AV, Subbaraju GV, Yasmin T, Bagchi D, Sen CK. 2006. Regulation of vascular responses to infl ammation: inducible matrix metalloproteinase-3 sensitive to antiinfl ammatory Boswellia. Antioxidants Redox Signaling 8: 653-660.
118. Saadane A, Masters S, DiDonato J, Li J, Berger M. 2007. Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and infl ammatory response in cystic fi brosis cells and mice. Am J Respir Cell Mol Biol 36: 728-736.
119. Safayhi H, Rall B, Sailer ER, Ammon HP. 1997. Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther 281: 460-463.
120. Sander O, Herborn G, Rau R. 1998. Is H15 (Extract of Boswellia serrata, 'incense') an effi cient supplementation to established drug therapy in RA? - Results of a double blinded pilot trial [Ist H15 (Harzextrakt von Boswellia serrata,1Weihraucha) eine sinnvolle Ergänzung zur etablierten medikamentösen Therapie der chronischen Polyarthritis? Ergebnisse einer doppelblinden Pilotstudie]. Zschr Rheumatol 57: 11-16.
121. Sandoval M, Charbonnet RM, Okuhama NN, Roberts J, Krenova Z, Trentacosti AM, Miller MJ. 2000. Cat's claw inhibits TNFá production and scavenges free radicals: Role in cytoprotection. Free Rad Biol Med 29: 71-78.
122. Sandoval M, Okuhama NN, Zhang XJ, Condezo LA, Lao J, Angeles FM, Musah RA, Bobrowski P, Miller MJ. 2002. Antiinfl ammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine 9: 325-337.
123. Santa Maria A, Lopez A, Diaz MM, Albán J, Galán de Mera A, Vicente Orellana JA, Pozuelo JM. 1997. Evaluation of the toxicity of Uncaria tomentosa by bioassays in vitro. J Ethnopharmacol 57: 183-187.
124. Santoli D, Zurier RB. 1989. Prostaglandin E precursor fatty acids inhibit human IL-2 production by a prostaglandin Eindependent mechanism. J Immunol 143: 1303-1309.
125. Schaser J, Bonaterra GA, Kelber O, Weiser D, Kinscherf R, Metz J. 2006. Untersuchung antiinfl ammatorischer Effekte des Phytopharmakons Phytodolor und seiner Einzelkomponenten in einem Monozyten-Testmodell. Perfusion 19: 76-77.
126. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. 2008a. Chapter 12: Interpreting results and drawing conclusions. In Cochrane Handbook for Systematic Reviews of Interventions, Higgins JPT, Green S (eds). Wiley-Blackwell: Chichester, UK.
127. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. 2008b. Chapter 11: Presenting results and 'Summary of fi ndings tables'. In Cochrane Handbook for Systematic Reviews of Interventions, Higgins JPT, Green S (eds). Wiley-Blackwell: Chichester, UK.
128. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. 2007. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NFkappaB-regulated gene products and TAK1-mediated NFkappaB activation. Blood 109: 2727-2735.
129. Sheng Y, Bryngelsson C, Pero RW. 2000. Enhanced DNA repair, immune function and reduced toxicity of C-Med-100, a novel aqueous extract from Uncaria tomentosa. J Ethnopharmacol 69: 115-126.
130. Siedle B, Gustavsson L, Johansson S, Murillo R, Castro V, Bohlin L, Merfort I. 2003. The effect of sesquiterpene lactones on the release of human neutrophil elastase. Biochem Pharmacol 65: 897-903.
131. Siemoneit U, Hofmann B, Kather N, Lamkemeyer T, Madlung J, Franke L, Schneider G, Jauch J, Poeckel D, Werz O. 2008. Identifi cation and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids. Biochem Pharmacol 5: 503-513.
132. Smolinski AT, Pestka JJ. 2003. Modulation of lipopolysaccharideinduced proinfl ammatory cytokine production in vitro and in vivo by the herbal constituents apigenin (chamomile), ginsenoside Rb(1) (ginseng) and parthenolide (feverfew). Food Chem Toxicol 41: 1381-1390.
133. Song YW, Lee EY, Koh EM, Cha HS, Yoo B, Lee CK, Baek HJ, Kim HA, Suh YI, Kang SW, Lee YJ, Jung HG. 2007. Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. Clin Ther 29: 862-873.
134. Strehl E, Schneider W, Elstner EF. 1995. Inhibition of dihydrofolate reductase activity by alcoholic extacts from Fraxinus excelsior, Populus tremula and Solidago virgaurea. Arneimittel-Forschung/Drug Res 45: 172-173.
135. Stoové MA, Andersen MB. 2003. What are we looking at, and how big is it? Phys Ther Sport 4: 93-97.
136. Sumner H, Salan U, Knight DW, Hoult JR. 1992. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 43: 2313-2320.
137. Takada Y, Ichikawa H, Badmaev V, Aggarwal BB. 2006. Acetyl-11-keto-beta- boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. J Immunology 76: 3127-3140.
138. Tao XL, Sun Y, Dong Y, Xiao YL, Hu DW, Shi YP, Zhu QL, Dai H, Zhang NZ. 1989. A prospective, controlled, double-blind, crossover study of Tripterygium wilfordii hook F in treatment of rheumatoid arthritis. Chinese Med J 102: 327-332.
139. Tao X, Schulze-Koops H, Ma L, Cai J, Mao Y, Lipsky PE. 1998. Effects of Tripterygium wilfordii hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum 41: 130-138.
140. Tao X, Younger J, Fan FZ, Wang B, Lipskey PE. 2002. Benefi t of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis. Arthritis Rheum 46: 1735-1743.
141. Tugwell P, Boers M, SImons L, Strand, Wells G. 2004. Evidencebased Rheumatology. BMJ Books: London.
142. Von Kruedener S, Schneider W, Elstner EF. Elstner EF. 1995. A combination of Populus tremula, Solidage viraurea and Fraxinus excelsior as an anti-infl ammatory and antirheumatic drug. Arzneimittel-Forschung/Drug Res 45: 169-171.
143. Wang B, Ma L, Tao X, Lipsky PE. 2004. Triptolide, an active component of the Chinese herbal remedy Tripterygium wilfordii Hook F, inhibits production of nitric oxide by decreasing inducible nitric oxide synthase gene transcription. Arthritis Rheum 50: 2995-2303.
144. Watson J, Byars ML, McGill P, Kelman AW. 1993. Cytokine and prostaglandin production by monocytes of volunteers and rheumatoid arthritis patients treated with dietary supplements of blackcurrant seed oil. Br J Rheumatol 32: 1055-1058.
145. Wildfeuer A, Neu IS, Safayhi H, Metzger G, Wehrmann M, Vogel U, Ammon HP. 1998. Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis. Arzneimittelforsch/Drug Res 48: 668-674.
146. Williams CA, Harborne JB, Geiger H, Hoult JR. 1999. The fl avonoids of Tanacetum parthenium and T. vulgare and their anti-infl ammatory properties. Phytochemistry 51: 417-423.
147. Wu H, Ye DJ, Zhao YZ, Wang SL. 1993. Effect of different preprations of ginger on blood coagulation time in mice. Zhongguo Zhon Yao Za Zhi 18: 147-149.
148. Wurm G, Baumann J, Geres U. 1982. Method for inhibiting cyclooxygenase and infl ammation using cherry biofl avonoids [Beeinfl ussung des Arachidonsäurestoffwechsels durch Flavonoide]. Dtsch Apotheker Ztg 122: 2062-2068.
149. Ziboh VA, Fletcher MP. 1992. Dose-response effects of dietary gamma-linolenic acid-enriched oils on human polymorphonuclear-neutrophil biosynthesis of leukotriene B4. Am J Clin Nutr 55: 39-45.
150. Ziboh VA, Naguwa S, Vang K, Wineinger J, Morrissey BM, Watnik M, Gershwin ME.2004. Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. Clin Dev Immunol 11: 13-21.
151. Zhou HF, Niu DB, Xue B, Li FQ, Liu XY, He QH, Wang XH, Wang XM. 2003. Triptolide inhibits TNF-alpha, IL-1 beta and NO production in primary microglial cultures. Neuroreport 14: 1091-1095.
152. Zurier RB, Rossetti RG, Jacobson EW, DeMarco DM, Liu NY, Temming JE, White BM, Laposata M. 1996. Gammalinolenic acid treatment of rheumatoid arthritis. Arthritis Rheum 39: 1808-1817.